Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22 Positive”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Testing effectiveness (Phase 2)Looking for participantsNCT02981628
What this trial is testing

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more
Children's Oncology Group 80
Testing effectiveness (Phase 2)Ended earlyNCT03094611
What this trial is testing

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Who this might be right for
CD22 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center 4
Early research (Phase 1)UnknownNCT02721407
What this trial is testing

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell Lymphoma+3 more
Xinqiao Hospital of Chongqing 20
Testing effectiveness (Phase 2)Study completedNCT01363297
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Pfizer 72
Testing effectiveness (Phase 2)Study completedNCT03289455
What this trial is testing

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic Leukemia+1 more
Autolus Limited 23
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Large-scale testing (Phase 3)Study completedNCT01564784
What this trial is testing

Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Pfizer 326
Testing effectiveness (Phase 2)Looking for participantsNCT03739814
What this trial is testing

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 84
Early research (Phase 1)UnknownNCT03999697
What this trial is testing

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Who this might be right for
Diffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre Lymphoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Study completedNCT01535989
What this trial is testing

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Who this might be right for
B-cell Lymphoma Refractory
Cristiana Sessa 25
Early research (Phase 1)Looking for participantsNCT06752785
What this trial is testing

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Who this might be right for
Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT00867087
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, B-Cell
Pfizer 64
Testing effectiveness (Phase 2)Study completedNCT01664910
What this trial is testing

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center 27
Early research (Phase 1)Study completedNCT02581878
What this trial is testing

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 21
Testing effectiveness (Phase 2)Study completedNCT00098839
What this trial is testing

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Recurrent Childhood Acute Lymphoblastic Leukemia
Children's Oncology Group 134
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Large-scale testing (Phase 3)Ended earlyNCT00562965
What this trial is testing

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Follicular
Pfizer 29
Load More Results